BioLineRx (BLRX) Tops Q2 EPS by 12c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. WCN
6. SPOT
7. BE
8. FIX
9. PNFP
10. NDAQ

Go back to BioLineRx (BLRX) Tops Q2 EPS by 12c

BioLineRx Reports Second Quarter 2022 Financial Results and Provides Corporate Update

August 16, 2022 7:00 AM EDT

- Submission of New Drug Application to FDA for Motixafortide in stem cell mobilization (SCM) for autologous stem cell transplantation expected within next 4-6 weeks -

- Announced appointment of commercial strategy and operations veteran Holly May as U.S.-based Chief Commercial Officer -

- Entered into collaboration agreement with GenFleet Therapeutics to advance Motixafortide in pancreatic cancer (PDAC) -

- Management to hold conference call today, August 16, at 10:00 am EDT -

TEL AVIV, Israel,... More